What's new in pancreatic cancer treatment pipeline?
There is still a substantial need for the development of new treatments for patients with pancreatic cancer. In this chapter, we will document that there is quite a bit of an increase in research activity with development in two major areas including (1) agents in the pipeline which already have hints of antitumor activity in patients with pancreatic cancer (therapeutic monoclonal antibodies and vaccines as well as more conventional cytotoxics), and; (2) agents in the pipeline which have just started (or will soon start) in clinical trial. These agents range from a gene-therapy approach to radiation enhancement to inhibitors of protein with increased expression in the very hypoxic pancreatic cancer tissue, to new monoclonal antibodies. With the level of investigational activity in pancreatic cancer it is very likely that several new therapeutic approaches to the disease will be forthcoming.
Von Hoff
Daniel D
DD
Translational Genomics Research Institute (TGen), 45 North 5th Street, Suite 600, Phoenix, AZ 85004, USA. dvh@tgen.org
D000256:Adenoviridae / Q000235:genetics; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use; D000068258:Bevacizumab; D019496:Cancer Vaccines / Q000627:therapeutic use; D000068818:Cetuximab; D003497:Cyclic N-Oxides / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004338:Drug Combinations; D005755:Gastrins / Q000627:therapeutic use; D006801:Humans; D009536:Niacinamide / Q000031:analogs & derivatives; D010094:Oxonic Acid / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000628:therapy*; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use; D000077157:Sorafenib; D013449:Sulfonamides / Q000627:therapeutic use; D005641:Tegafur / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use; D000093542:Gemcitabine
C487781:(E)-4-(2-(2-(N-acetyl-N-(4-methoxybenzenesulfonyl)amino)stilbazole)) 1-oxide; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D019496:Cancer Vaccines; D003497:Cyclic N-Oxides; D004338:Drug Combinations; D005755:Gastrins; D010671:Phenylurea Compounds; D011725:Pyridines; D013449:Sulfonamides; D014409:Tumor Necrosis Factor-alpha; C482698:gastrin immunogen; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D009536:Niacinamide; D000068258:Bevacizumab; D010094:Oxonic Acid; D000077157:Sorafenib; D000068818:Cetuximab; D000093542:Gemcitabine